

Coenzyme Q10 therapy in lithotripsy in patients with renal lithiasis

Submission date 20/02/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 19/03/2010	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 19/03/2010	Condition category Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Julia Carrasco

Contact details
Hu Reina Sofia
Servicio de Urologia
3ª Planta Edificio de Consultas
Avda Menendez Pidal S/N
Cordoba
Spain
14004
+34 629 80 37 51
juliacv83@hotmail.com

Additional identifiers

Study information

Scientific Title
Coenzyme Q10 therapy in lithotripsy in patients with renal lithiasis: a prospective randomised double-blind trial

Acronym

Q10LT

Study objectives

Urinary tract lithiasis is associated with renal damage secondary to the appearance of inflammatory changes and imbalances in hormone regulation of angiotensin II axis, which finally lead to the development of fibrosis. Today it is accepted that the treatment of initial choice for most cases of urolithiasis is the application of extracorporeal shockwave lithotripsy that by shock wave emission causes fragmentation of the calculus, allowing their elimination by the excretory way. Associated to the injuries by lithotripsy appears inflammatory phenomena and vasoactive hormonal. In both cases, the final common mediator lies in oxidative imbalance.

Therefore, the use of drugs with antioxidant capacity, such as co-Q10 might reduce kidney damage associated with the application of lithotripsy for patients with urinary tract lithiasis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Local Ethics Committee of the Reina Sofia Hospital approved in February 2009

Study design

Prospective randomised controlled double-blind trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Renal lithiasis

Interventions

Coenzyme Q10 is administered (two 30 mg capsules every 8 hours) for 14 days versus placebo.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Coenzyme Q10

Primary outcome(s)

Determination of glomerular filtration rate (MDRD), measured in June 2010 and September 2010

Key secondary outcome(s)

Measured in June 2010 and September 2010:

1. Biochemical markers of oxidative stress:

1.1. MDA

1.2. Glutathione

1.3. SOD

1.4. Catalase

Completion date

01/09/2010

Eligibility

Key inclusion criteria

1. Adult patients aged 25 to 65 years (either sex) with urinary tract lithiasis
2. Candidates to applying lithotripsy
3. Lithiasis located in the renal pelvis and/or calyx

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Patients undergoing lithotripsy at the time of initiating the study
2. Patients with previously diagnosed renal lithotripsy
3. Patients treated with calcium channel blockers
4. Complications of lithotripsy that determine the need for further intervention in the study period
5. Taking antiplatelet 3 days before extracorporeal shock-wave lithotripsy (ESWL) session
6. Controlled clotting disorders
7. Complete distal obstruction to the calculation to be treated
8. Unrecovery kidney
9. Allergy to the components of medications
10. Inability to understand or psychosocial misadjustment
11. Refusal to sign informed consent

Date of first enrolment

01/05/2009

Date of final enrolment

01/09/2010

Locations

Countries of recruitment

Spain

Study participating centre

Hu Reina Sofia

Cordoba

Spain

14004

Sponsor information

Organisation

Association of Urology Research and Development (Asociacion de Urologia y Desarrollo de la Investigacion) (Spain)

ROR

<https://ror.org/039xbga15>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Hu Reina Sofia Hospital (Spain)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration